Co-founder & Chief Executive Officer
Henry C.H. Liu
Dr. Henry Liu is the co-founder and the CEO of Libo Pharma Corp., and shoulders the responsibility of leading, guiding, and overseeing the entire operation, growth and development of the company. Before appointed to be the CEO, Dr. Liu served as Vice President of Libo from 2017 to 2020.
Prior to leading the corporate spin-off of Libo Pharma Corp. from its parent company, Lihpao Life Sciences Corp. (LLSC) in 2017, Dr. Liu worked as an Executive Specialist for the General Manager at LLSC and assumed a wide variety of responsibilities: he directed and supervised several collaborative Next Generation Sequencing research projects in collaboration with clinical oncologists for developing companion diagnostics kits; established and managed international business relations and collaborations; evaluated in/out-licensing projects and oversaw technology transfer. Among all these duties, he also led, planned, prepared and acquired funding for establishing Libo Pharma Corp.
Dr. Liu received his BSc and MSc in Bioengineering from UC Berkeley and UC San Diego, respectively. He is also an active member of Taiwan Joint Commission of Precision Medicine.
Prior to leading the corporate spin-off of Libo Pharma Corp. from its parent company, Lihpao Life Sciences Corp. (LLSC) in 2017, Dr. Liu worked as an Executive Specialist for the General Manager at LLSC and assumed a wide variety of responsibilities: he directed and supervised several collaborative Next Generation Sequencing research projects in collaboration with clinical oncologists for developing companion diagnostics kits; established and managed international business relations and collaborations; evaluated in/out-licensing projects and oversaw technology transfer. Among all these duties, he also led, planned, prepared and acquired funding for establishing Libo Pharma Corp.
Dr. Liu received his BSc and MSc in Bioengineering from UC Berkeley and UC San Diego, respectively. He is also an active member of Taiwan Joint Commission of Precision Medicine.
Co-founder & BD&L Director
Mandy M.-N. Lee
Mandy M.-N. Lee co-founded Libo Pharma Corp. (Libo) with Dr. Henry Liu in 2017, and was named Director of Business Development & Licensing in 2019 . She is responsible for the company’s business development activities, including strategic planning, product portfolio and IP management, in/out-licensing evaluation, technology transfer oversight, and strategic alliance management . Prior to this role, Ms. Lee served as the company’s BD & IP Operations Manager and worked in business planning, fund acquisition, IP analysis, and international technology transfer networking.
Before leading the spin-off of Libo from Lihpao Life Sciences Corp. (LLSC), Ms. Lee was Project Manager at LLSC for several important programs pertaining to technology transfer, patent deployment, and preparation for subsidiary corporation . Prior to that, she was the Core Lab Manager directing numerous R&D projects in the development of oral vaccine platform and dendritic cell immunotherapy.
Mandy M.-N. Lee earned her MSc. in Biological Sciences and Technology from National Chiao Tung University, where she is also a PhD candidate. In addition, she received intensive training in business and IP management from top programs such as Foster school of Business executive education Multi-discipline management of technology program (University of Washington), Taiwan Intellectual Property Training Academy, and the Europe IPRs programs in Munich (BOEHMERT & BOEHMERT law firm)
Before leading the spin-off of Libo from Lihpao Life Sciences Corp. (LLSC), Ms. Lee was Project Manager at LLSC for several important programs pertaining to technology transfer, patent deployment, and preparation for subsidiary corporation . Prior to that, she was the Core Lab Manager directing numerous R&D projects in the development of oral vaccine platform and dendritic cell immunotherapy.
Mandy M.-N. Lee earned her MSc. in Biological Sciences and Technology from National Chiao Tung University, where she is also a PhD candidate. In addition, she received intensive training in business and IP management from top programs such as Foster school of Business executive education Multi-discipline management of technology program (University of Washington), Taiwan Intellectual Property Training Academy, and the Europe IPRs programs in Munich (BOEHMERT & BOEHMERT law firm)
Co-founder & Chief Strategy Officer
Peter Tsai
Mr.Tsai has more than 13 years of experience in vaccine and biologic development and commercialization. Before taking on his current role, he spent 12 years at Merck Sharp and Dohme (MSD), serving in several research & development, technology, and manufacturing roles with increasing scope of responsibilities.
Mr.Tsai was Director of Global Vaccine Technical Operations at MSD from 2019-2021, during which he was responsible for the delivery of a brand-new vaccine commercial manufacturing asset and process. Prior to that, he led process development and commercialization teams supporting pipeline vaccine programs at MSD. He oversaw end-to-end programs starting from early/late-stage process development to commercial manufacturing and licensures (BLA/NDA). He successfully led multiple internal and external commercial technology transfers and has achieved significant milestones in multiple vaccine product and facility approvals during his tenure at MSD.
Mr.Tsai also recently helped founded a veterinary vaccine company developing oncology solutions for companion animals.
Before joining the industry, Mr.Tsai obtained his Master Degree from University of Pennsylvania and a B.A degree from University of British Columbia.
Mr.Tsai was Director of Global Vaccine Technical Operations at MSD from 2019-2021, during which he was responsible for the delivery of a brand-new vaccine commercial manufacturing asset and process. Prior to that, he led process development and commercialization teams supporting pipeline vaccine programs at MSD. He oversaw end-to-end programs starting from early/late-stage process development to commercial manufacturing and licensures (BLA/NDA). He successfully led multiple internal and external commercial technology transfers and has achieved significant milestones in multiple vaccine product and facility approvals during his tenure at MSD.
Mr.Tsai also recently helped founded a veterinary vaccine company developing oncology solutions for companion animals.
Before joining the industry, Mr.Tsai obtained his Master Degree from University of Pennsylvania and a B.A degree from University of British Columbia.
Chief Medical Officer
Simon R.K. Hsieh
Dr. Simon Hsieh was appointed as the Chief Medical Officer (CMO) at Libo Pharma Corp. in 2020 , and currently is also the superintendent of Evergreen Health Precision Medicine Clinic. As the CMO of Libo, he oversees and directs the entire clinical development program across multiple therapeutic indications.
Prior to joining Libo in 2018 as Medical Advisor, Dr. Hsieh had over 30 years of experience in Hematology and Oncology.
During his numerous years of clinical practice, he assumed many important roles at different medical centers: he served as the Chief of the Division of Hematology and Oncology, Director of Cancer Center, and Senior Consultant to the Superintendent at Taipei MacKay Memorial Hospital—Taipei, and Chief of the Cancer Research Ward at Taipei Medical University Hospital. In addition, he was also the President of Taiwan Oncology Society (TOS) and Taiwan Society of Cancer Palliative Medicine. At present, he is appointed the Chairman of Taiwan Total Care Cancer Foundation and Chair of Data Safety Review Board for Taiwan Cooperative Oncology Group (TCOG)
Dr. Hsieh obtained his medical degree from National Yang Ming University, and received further training in hematology and oncology from Medical Oncologist Training Program at Institute of Biomedical Sciences, Academia Sinica, Taipei. He was also a Clinical Fellow at the Wilmot Cancer Institute of the University of Rochester Medical Center, New York .
Prior to joining Libo in 2018 as Medical Advisor, Dr. Hsieh had over 30 years of experience in Hematology and Oncology.
During his numerous years of clinical practice, he assumed many important roles at different medical centers: he served as the Chief of the Division of Hematology and Oncology, Director of Cancer Center, and Senior Consultant to the Superintendent at Taipei MacKay Memorial Hospital—Taipei, and Chief of the Cancer Research Ward at Taipei Medical University Hospital. In addition, he was also the President of Taiwan Oncology Society (TOS) and Taiwan Society of Cancer Palliative Medicine. At present, he is appointed the Chairman of Taiwan Total Care Cancer Foundation and Chair of Data Safety Review Board for Taiwan Cooperative Oncology Group (TCOG)
Dr. Hsieh obtained his medical degree from National Yang Ming University, and received further training in hematology and oncology from Medical Oncologist Training Program at Institute of Biomedical Sciences, Academia Sinica, Taipei. He was also a Clinical Fellow at the Wilmot Cancer Institute of the University of Rochester Medical Center, New York .
© Copyright | LIBO PHARMA CORP. | All rights reserved | Private Policy 2024